Le Lézard
Classified in: Health, Science and technology, Business
Subject: RCN

Pursuant Health Completes Funding Round to Drive New Product Initiatives


ATLANTA, June 23, 2022 /PRNewswire/ -- Pursuant Health, a health data management platform with a network of 4,600 retail-based health kiosks that provide accessible and affordable health screenings, has successfully completed a recapitalization that provides $4.3 million of cash and reduces the Company's debt from $16.7 million to $2.3 million ? significantly improving the Company's financial position.

"This is excellent news for the future of the company and the progression of our product initiatives, most notably the introduction of imaging technology to expand the frontier of non-invasive health screening," said Donnie Helms, Chief Financial Officer of Pursuant Health.

Larry Gerdes, Chief Executive Officer, added, "While investors responded favorably to our mission of making health care as convenient as possible for the individual, I also believe they appreciate how we run the company and the financial discipline we have from top to bottom."

Highlights of the transaction include:

About Pursuant Health

With a network of over 4,600 health kiosks located in high-traffic retail pharmacies throughout the country, we enable people to regularly check in with their health when it is convenient for them. Our kiosks are HIPAA-Compliant, FDA-Cleared Class II Medical Devices that provide free health screenings to individuals, while our data platform helps them track their metrics over time and understand their personal health risks.

SOURCE Pursuant Health


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: